RMDN2-AS1

Across TCGA pan-cancer cohorts, RMDN2-AS1 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated RMDN2-AS1 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RMDN2-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RMDN2-AS1 expression acts as an unfavorable survival marker, although some lineages such as PAAD and LUAD show a favorable association.

ACC, PAAD, and KIRC are the cancer types where RMDN2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.659	0.913	<.001	106	view →
PAAD	DFS	Median	All	0.608	0.372	<.001	85	view →
KIRC	OS	Tertile	All	0.509	0.709	<.001	82	view →
LIHC	DFS	Median	All	0.226	0.352	.001	53	view →
KIRP	DFS	Quartile	II,III,IV	0.191	0.940	.001	51	view →
BLCA	DFS	Tertile	All	0.477	0.699	.005	35	view →
LGG	OS	Quartile	All	0.419	0.664	<.001	33	view →
LUAD	OS	Tertile	All	0.860	0.678	.003	32	view →
KICH	OS	Median	III,IV	0.556	1.000	.010	29	view →
UVM	OS	Median	III,IV	0.258	0.836	.007	21	view →
THCA	DFS	Tertile	II,III,IV	0.765	0.946	.001	21	view →
PRAD	DFS	Tertile	All	0.877	0.751	.002	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

RMDN2-AS1–ACC (OS)

Open the ACC breakdown →